| Model |
AUC* |
Sensitivity (%) |
Specificity (%) |
| Simple treatment history |
|
|
| Cross validation |
|
|
|
| 1 |
0.829 |
63.64 |
84.23 |
| 2 |
0.824 |
67.51 |
81.68 |
| 3 |
0.827 |
65.24 |
80.43 |
| 4 |
0.784 |
61.21 |
79.60 |
| 5 |
0.813 |
64.08 |
80.72 |
| Mean |
0.815 |
64.34 |
81.33 |
| |
|
|
|
| Committee average performance with 375 test TCEs |
0.870 |
66.67 |
90.48 |
| 95% CI |
0.87-0.97 |
41-87 |
87-93 |
|
|
|
|
| Individual treatment history |
|
|
|
| Cross validation |
|
|
|
| 1 |
0.837 |
64.86 |
85.06 |
| 2 |
0.821 |
61.18 |
84.42 |
| 3 |
0.834 |
62.52 |
86.56 |
| 4 |
0.798 |
60.43 |
83.49 |
| 5 |
0.811 |
61.55 |
81.26 |
| Mean |
0.820 |
62.11 |
84.16 |
| |
|
|
|
| Committee average performance with 375 test TCEs |
0.855 |
61.11 |
87.47 |
| 95% CI |
0.76-0.95 |
36-83 |
85-92 |
| |
|
|
|
| Results from common rules-based genotype interpretation systems** |
| Stanford HIVdb |
0.591 |
47.06 |
41.26 |
| 95% CI |
0.49-0.69 |
[23, 72] |
[36, 47] |
| ANRS v2011.05 |
0.573 |
23.53 |
61.03 |
| 95% CI |
0.45-0.69 |
[7,50] |
[56,66] |
| REGA v8.0.2 |
0.566 |
35.29 |
54.44 |
| 95% CI |
0.44-0.69 |
[14, 62] |
[49, 60] |
*AUC=area under the (receiver-operator characteristic) curve.
** Based on 366 TCEs after those containing maraviroc or raltegravir were removed |
